Literature DB >> 3613786

Treatment of hypopharyngeal carcinoma: a 10-year review of 1,362 cases.

T F Pingree, R K Davis, O Reichman, L Derrick.   

Abstract

A computer search of cancer patients enrolled in the Rocky Mountain Cancer Data System between 1973 to 1983 revealed 1,362 patients with hypopharyngeal cancer, 1,208 of whom could be staged by the American Joint Committee on cancer staging criteria. Stage I and II patients comprised 17.5% while 71% were either stages III or IV. The distant metastatic rate in advanced stage patients was 24%. Survivals for all treated patients were 65% at 1 year, 33.5% at 3 years, and 25% at 5 years. Three-year survivals were 54.5% for the surgery only group, 41.6% for the combined therapy group, and 17.7% for the irradiation only group. Five-year survivals for the surgery only group were 39.8%, combined therapy, 31.8%, and irradiation only 11.5%. These figures are actuarially corrected. Twenty-two percent of combined therapy patients had preoperative irradiation versus 78% who had postoperative irradiation. There was no statistically significant difference seen between these two groups.

Entities:  

Mesh:

Year:  1987        PMID: 3613786

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  13 in total

Review 1.  Minimally invasive techniques for head and neck malignancies: current indications, outcomes and future directions.

Authors:  Dana M Hartl; Alfio Ferlito; Carl E Silver; Robert P Takes; Sandro J Stoeckli; Carlos Suárez; Juan P Rodrigo; Andreas M Sesterhenn; Carl H Snyderman; David J Terris; Eric M Genden; Alessandra Rinaldo
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-05-12       Impact factor: 2.503

2.  Hypopharyngeal cancer: looking back, moving forward.

Authors:  D Day; A R Hansen; L L Siu
Journal:  Curr Oncol       Date:  2016-08-12       Impact factor: 3.677

3.  Hypopharyngeal carcinoma in Finland from 1990-1999.

Authors:  Jussi Laranne; Leif Bäck; Petri Koivunen; Matti Pukkila; Jaakko Pulkkinen; Reidar Grénman
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-10-22       Impact factor: 2.503

4.  Clinical outcomes of weekly cisplatin chemoradiotherapy for patients with pyriform sinus cancer.

Authors:  Tomohiro Sakashita; Akihiro Homma; Hiromitsu Hatakeyama; Jun Furusawa; Satoshi Kano; Takatsugu Mizumachi; Satoshi Iizuka; Rikiya Onimaru; Kazuhiko Tsuchiya; Koichi Yasuda; Hiroki Shirato; Satoshi Fukuda
Journal:  Int J Clin Oncol       Date:  2015-03-25       Impact factor: 3.402

5.  Radical resection or chemoradiotherapy for cervical esophageal cancer?

Authors:  Shah-Hwa Chou; Hsien-Pin Li; Jui-Ying Lee; Meei-Feng Huang; Chia-Hua Lee; Ka-Wo Lee
Journal:  World J Surg       Date:  2010-08       Impact factor: 3.352

6.  Concurrent radiochemotherapy in advanced hypopharyngeal cancer.

Authors:  Valentina Krstevska; Igor Stojkovski; Dusko Lukarski
Journal:  Radiat Oncol       Date:  2010-05-18       Impact factor: 3.481

7.  c-Jun and Camk2a contribute to the drug resistance of induction docetaxel/cisplatin/5-fluorouracil in hypopharyngeal carcinoma.

Authors:  Shuzhou Liu; Meng Lian; Jugao Fang; Jie Zhai; Xixi Shen; Ru Wang
Journal:  Int J Clin Exp Pathol       Date:  2018-09-01

8.  Supracricoid hemilaryngopharyngectomy for selected pyriform sinus carcinoma patients--a retrospective chart review.

Authors:  George X Papacharalampous; Georgios P Kotsis; Petros V Vlastarakos; Alexandros Georgolios; Ioannis Seggas; Ioannis E Yiotakis; Leonidas Manolopoulos
Journal:  World J Surg Oncol       Date:  2009-08-11       Impact factor: 2.754

9.  Traditional transcutaneous approaches in head and neck surgery.

Authors:  Ulrich R Goessler
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20

10.  Transoral treatment strategies for head and neck tumors.

Authors:  Christoph Arens
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2012-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.